QI
BMRN icon

Qtron Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Qtron Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,358
Closed -$246K – 458
2026
Q1 		$246K Hold
4,358
– – 0.03% 403
2025
Q4 		$259K Sell
4,358
-9,875
-69% -$538K 0.03% 408
2025
Q3 		$771K Buy
14,233
+2,201
+18% +$126K 0.1% 242
2025
Q2 		$661K Buy
12,032
+8,774
+269% +$517K 0.08% 283
2025
Q1 		$230K Buy
+3,258
New +$219K 0.03% 367

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Qtron Investments's BMRN Position: Q2 2026 in Review

Qtron Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 4,358 shares — an estimated $246K sold.

Qtron Investments first reported a position in BMRN in Q1 2025 and held it in 5 quarters. The position peaked at $771K in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Qtron Investments reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Qtron Investments sold 4,358 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $246K.
  • Qtron Investments first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Qtron Investments's BioMarin Pharmaceuticals position peaked at $771K in Q3 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Qtron Investments's 13F filing for Q2 2026, filed 13 Aug 2026.